Gastric Cancer Clinical Trial
Official title:
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating Combination of TST001, Nivolumab and Chemotherapy as First-Line Treatment in Subjects With Claudin18.2 Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (Gastric/GEJ) Adenocarcinoma
Gastric/GEJ adenocarcinomas are aggressive tumors with a high probability of death. Current treatment guidelines include two-drug cytotoxic chemotherapy with a fluoropyrimidine (mFOLFOX6: capecitabine or fluorouracil) and a platinum-based agent (CapOx: oxaliplatin or cisplatin). In addition, the FDA has recently approved nivolumab, a PD-1 checkpoint inhibitor, in combination with chemotherapy as first line treatment for advanced or metastatic gastric/GEJ cancer. TST001 is a recombinant humanized monoclonal antibody against Claudin (a tumor marker found in gastric/GEJ cancer. In this study, the combination therapy of chemotherapy or chemotherapy and nivolumab with and without TST001 (a novel recombinant humanized antibody) could provide additional benefits to the management of these tumors.
Status | Not yet recruiting |
Enrollment | 950 |
Est. completion date | January 31, 2026 |
Est. primary completion date | October 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically or cytologically confirmed diagnosis of previously untreated, unresectable locally advanced or metastatic gastric/GEJ adenocarcinoma. - Must be willing and able to provide archival or fresh tissue sample, a formalin-fixed, paraffin-embedded (FFPE) block, or 10 or more unstained, freshly cut, serial sections (on slides) from an FFPE tumor specimen from a tumor lesion (either primary or metastatic) not previously irradiated or fresh biopsy tissue fixed in formalin solution. FFPE tissue blocks are preferred to slides. - Biomarkers positive CDLN18.2 expression and PD-L1 CPS Status - Must have at least one measurable lesion or evaluable disease - Subjects should be eligible to receive chemotherapy per local guidelines Exclusion Criteria: - Any prior systemic anticancer treatment (chemotherapy, immunotherapy, biologic therapy, or targeted therapy) for gastric/GEJ adenocarcinoma. - Has received prior radiotherapy within 2 weeks before randomization - Anti-CLDN18.2 agents at any time. - Any traditional Chinese medicine or proprietary Chinese medicine with anti-tumor effect within 7 days before randomization. - Any vaccines (live, attenuated, or research vaccines) within 30 days of dosing. - Gastrointestinal abnormalities including: Documented unresolved gastric outlet obstruction or persistent vomiting defined as =3 episodes within 24 hours within 2 weeks before randomization. Uncontrolled peptic ulcer disease Clinically significant gastrointestinal bleeding as evidenced by hematemesis, hematochezia, or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy - Squamous cell or undifferentiated gastric cancer - HER2 positive tumor defined as immunohistochemistry 3+ or ISH/FISH positive - Known additional malignancy that is progressing or has required active treatment within the past 5 years. - Known symptomatic or progressive CNS metastases and/or carcinomatous meningitis. - Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior randomization. - Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of immunomodulatory agents, corticosteroids or immunosuppressive drugs). - Has a history of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease. - Has Grade = 2 peripheral sensory neuropathy - Has an active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy within 2 weeks of Cycle 1 Day 1 (first dose of study treatment). - Has a known history of HIV infection. Subjects with a CD4+ T cell count > 350 cells/µL and no history of an AIDS-defining opportunistic infections are eligible for entry. HIV testing is required only for the subject's safety at the discretion of the investigator. - Has active viral hepatitis. Subjects with serologic evidence of HBV infection (defined by a positive hepatitis B surface antigen test) who have a viral load below the limit quantification (HBV DNA titer < 1000 cps/mL or 200 IU/mL) and are not currently on viral suppressive therapy may be eligible. Subjects with a history of HCV infection should have completed curative antiviral treatment and have a viral load below the limit of quantification. - Major surgery within 4 weeks prior to study entry; Minor surgery within 2 weeks prior to study entry. Has not recovered from the procedure and/or any complications from the surgery prior to randomization. - Severe cardiovascular disease, including cerebral vascular accident, transient ischemic attack, myocardial infarction, or unstable angina, NYHA class III or IV heart failure or = Grade 2 uncontrolled arrhythmia within 6 months of screening. - Corrected QTcF =470 ms (male) and =480 ms (female) at baseline (Fridericia); taking concomitant medications that would prolong the QT interval; or with family history of long QT syndrome - Prior stem cell, bone marrow or solid organ transplant. - Has a history or current evidence of any condition (including psychiatric or substance abuse disorder), therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Suzhou Transcenta Therapeutics Co., Ltd. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression free survival (PFS) based on RECIST (1.1) | Compare PFS of patients treated with TST001 or Placebo in addition to CapOx or mFOLFOX6 and nivolumab or CapOx or mFOLFOX6 | From date of randomization until the date of documented progression, assessed up to 100 days after last dose | |
Secondary | Overall Survival (OS) based on RESIST (log-rank test) | Compare OS of patients treated with TST001 or Placebo in addition to CapOx or mFOLFOX6 and nivolumab or CapOx or mFOLFOX6 | rom date of randomization until the date of documented progression, assessed up to 100 days after last dose | |
Secondary | Overall Response Rate (ORR) based on RESIST progressive disease (log-rank test) | Compare complete response (CR) or partial response (PR) between treatment arms of patients treated with TST001 or Placebo in addition to CapOx or mFOLFOX6 and nivolumab or CapOx or mFOLFOX6. | From date of randomization until the date of documented CR or PR assessed up to 100 days after last dose | |
Secondary | Quality of Life (QOL) assessed on EuroQol EQ5D-5L | Change in QOL assessments from baseline of patients treated with TST001 or Placebo in addition to mFOLFOX6 and nivolumab or CapOx or mFOLFOX6. Assessments include Cancer QOL questionnaires (QLC-STO22, EQ5D-5L, and QLQ-C30) | From date of randomization until the date of documented progression, assessed up to 100 days after last dose | |
Secondary | Disease Control Rate (DCR) based on RESIST assessed as the percentage of subjects with measurable disease | Compare complete response (CR), partial response (PR), or stable disease (SD) between treatment arms of patients treated with TST001 or Placebo in addition to CapOx or mFOLFOX6 and nivolumab or CapOx or mFOLFOX6. | From date of randomization until the date of documented progression, assessed up to 100 days after last dose | |
Secondary | Duration of Response (DOR) based on RESIST (log-rank test) | Compare duration of response between treatment arms of patients treated with TST001 or Placebo in addition to CapOx or mFOLFOX6 and nivolumab or CapOx or mFOLFOX6. | From date of randomization until the date of documented progression, assessed up to 100 days after last dose | |
Secondary | Time to Response (TTR) of progression based on RESIST | Compare the time of response between treatment arms of patients treated with TST001 or Placebo in addition to CapOx or mFOLFOX6 and nivolumab or CapOx or mFOLFOX6 based on CR or PR. | From date of randomization until the date of documented progression, assessed up to 100 days after last dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05551416 -
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
|
||
Completed |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03219593 -
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT05536102 -
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT04082364 -
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03766607 -
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT01924533 -
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
|
Phase 3 | |
Terminated |
NCT01641939 -
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT04908813 -
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04249739 -
Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
|
Phase 2 | |
Recruiting |
NCT05514158 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
|
Phase 1 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 |